0000876378 us-gaap:AdditionalPaidInCapitalMember 2007-01-01 2007-12-31 0000876378 us-gaap:AdditionalPaidInCapitalMember 2006-01-01 2006-12-31 0000876378 us-gaap:CommonStockMember 2007-01-01 2007-12-31 0000876378 us-gaap:CommonStockMember 2006-01-01 2006-12-31 0000876378 us-gaap:BoardOfDirectorsChairmanMember sfes:TwoThousandTwelvePipeInvestorsMember 2012-02-01 2012-02-29 0000876378 sfes:TwoThousandTwelvePipeInvestorsMember sfes:PresidentAndChiefExecutiveOfficerMember 2012-02-01 2012-02-29 0000876378 sfes:BoardOfDirectorsMember sfes:TwoThousandTwelvePipeInvestorsMember 2012-02-01 2012-02-29 0000876378 sfes:TwoThousandTwelvePipeInvestorsMember sfes:BoardOfDirectorsChairmanOneMember 2012-02-01 2012-02-29 0000876378 us-gaap:CommonStockMember 2012-01-01 2012-09-30 0000876378 sfes:DeficitAccumulatedDuringDevelopmentStageMember 2012-09-30 0000876378 us-gaap:AdditionalPaidInCapitalMember 2011-12-31 0000876378 sfes:DeficitAccumulatedDuringDevelopmentStageMember 2011-12-31 0000876378 us-gaap:AdditionalPaidInCapitalMember 2010-12-31 0000876378 sfes:DeficitAccumulatedDuringDevelopmentStageMember 2010-12-31 0000876378 us-gaap:AdditionalPaidInCapitalMember 2009-12-31 0000876378 sfes:DeficitAccumulatedDuringDevelopmentStageMember 2009-12-31 0000876378 2009-12-31 0000876378 us-gaap:AdditionalPaidInCapitalMember 2008-12-31 0000876378 sfes:DeficitAccumulatedDuringDevelopmentStageMember 2008-12-31 0000876378 2008-12-31 0000876378 us-gaap:AdditionalPaidInCapitalMember 2007-12-31 0000876378 sfes:DeficitAccumulatedDuringDevelopmentStageMember 2007-12-31 0000876378 2007-12-31 0000876378 us-gaap:AdditionalPaidInCapitalMember 2006-12-31 0000876378 sfes:DeficitAccumulatedDuringDevelopmentStageMember 2006-12-31 0000876378 2006-12-31 0000876378 us-gaap:AdditionalPaidInCapitalMember 2005-12-31 0000876378 sfes:DeficitAccumulatedDuringDevelopmentStageMember 2005-12-31 0000876378 2005-12-31 0000876378 us-gaap:AdditionalPaidInCapitalMember 2005-09-15 0000876378 sfes:DeficitAccumulatedDuringDevelopmentStageMember 2005-09-15 0000876378 us-gaap:PreferredStockMember 2012-09-30 0000876378 us-gaap:PreferredStockMember 2011-12-31 0000876378 us-gaap:CommonStockMember 2011-12-31 0000876378 us-gaap:PreferredStockMember 2010-12-31 0000876378 us-gaap:CommonStockMember 2010-12-31 0000876378 us-gaap:PreferredStockMember 2009-12-31 0000876378 us-gaap:CommonStockMember 2009-12-31 0000876378 us-gaap:PreferredStockMember 2008-12-31 0000876378 us-gaap:CommonStockMember 2008-12-31 0000876378 us-gaap:PreferredStockMember 2007-12-31 0000876378 us-gaap:CommonStockMember 2007-12-31 0000876378 us-gaap:PreferredStockMember 2006-12-31 0000876378 us-gaap:CommonStockMember 2006-12-31 0000876378 us-gaap:PreferredStockMember 2005-12-31 0000876378 us-gaap:CommonStockMember 2005-12-31 0000876378 us-gaap:PreferredStockMember 2005-09-15 0000876378 us-gaap:CommonStockMember 2005-09-15 0000876378 us-gaap:MinimumMember 2012-01-01 2012-12-31 0000876378 us-gaap:MaximumMember 2012-01-01 2012-12-31 0000876378 sfes:ConsultantsMember 2012-01-01 2012-09-30 0000876378 sfes:ConsultantsMember 2011-01-01 2011-09-30 0000876378 2005-09-15 0000876378 us-gaap:SoftwareMember us-gaap:MinimumMember 2012-01-01 2012-09-30 0000876378 us-gaap:SoftwareMember us-gaap:MaximumMember 2012-01-01 2012-09-30 0000876378 sfes:FurnitureFixturesAndLeaseholdImprovementsMember us-gaap:MinimumMember 2012-01-01 2012-09-30 0000876378 sfes:FurnitureFixturesAndLeaseholdImprovementsMember us-gaap:MaximumMember 2012-01-01 2012-09-30 0000876378 us-gaap:MachineryAndEquipmentMember 2012-01-01 2012-09-30 0000876378 us-gaap:SoftwareMember 2012-09-30 0000876378 us-gaap:MachineryAndEquipmentMember 2012-09-30 0000876378 sfes:FurnitureFixturesAndLeaseholdImprovementsMember 2012-09-30 0000876378 us-gaap:SoftwareMember 2011-12-31 0000876378 us-gaap:MachineryAndEquipmentMember 2011-12-31 0000876378 sfes:FurnitureFixturesAndLeaseholdImprovementsMember 2011-12-31 0000876378 us-gaap:PreferredStockMember 2008-01-08 0000876378 sfes:MiamiMember 2012-07-01 2012-09-30 0000876378 sfes:CreightonRoyaltyAgreementMember 2012-07-01 2012-09-30 0000876378 sfes:MiamiMember 2012-01-01 2012-09-30 0000876378 sfes:MiamiMember 2011-07-01 2011-09-30 0000876378 sfes:CreightonRoyaltyAgreementMember 2011-07-01 2011-09-30 0000876378 sfes:MiamiMember 2011-01-01 2011-09-30 0000876378 sfes:CreightonRoyaltyAgreementMember 2011-01-01 2011-09-30 0000876378 sfes:DeficitAccumulatedDuringDevelopmentStageMember 2012-01-01 2012-09-30 0000876378 sfes:DeficitAccumulatedDuringDevelopmentStageMember 2011-01-01 2011-12-31 0000876378 sfes:DeficitAccumulatedDuringDevelopmentStageMember 2010-01-01 2010-12-31 0000876378 sfes:DeficitAccumulatedDuringDevelopmentStageMember 2009-01-01 2009-12-31 0000876378 sfes:DeficitAccumulatedDuringDevelopmentStageMember 2008-01-01 2008-12-31 0000876378 sfes:DeficitAccumulatedDuringDevelopmentStageMember 2007-01-01 2007-12-31 0000876378 2007-01-01 2007-12-31 0000876378 sfes:DeficitAccumulatedDuringDevelopmentStageMember 2006-01-01 2006-12-31 0000876378 2006-01-01 2006-12-31 0000876378 sfes:DeficitAccumulatedDuringDevelopmentStageMember 2005-09-16 2005-12-31 0000876378 sfes:MrSpragensMember 2012-09-30 0000876378 sfes:MrSpragensAndFrostGroupMember 2012-09-30 0000876378 sfes:FrostGroupMember 2012-09-30 0000876378 sfes:CreditFacilityMember 2012-07-01 2012-09-30 0000876378 sfes:CreditFacilityMember 2012-01-01 2012-09-30 0000876378 us-gaap:CommonStockMember 2008-01-08 0000876378 us-gaap:CommonStockMember 2012-09-30 0000876378 us-gaap:AdditionalPaidInCapitalMember 2012-09-30 0000876378 us-gaap:CommonStockMember 2008-01-08 0000876378 2012-06-19 0000876378 2011-09-30 0000876378 2010-12-31 0000876378 us-gaap:CommonStockMember sfes:CellularMember 2007-09-01 2007-09-30 0000876378 us-gaap:WarrantMember 2012-01-01 2012-09-30 0000876378 us-gaap:StockOptionsMember 2012-01-01 2012-09-30 0000876378 us-gaap:WarrantMember 2011-01-01 2011-09-30 0000876378 us-gaap:StockOptionsMember 2011-01-01 2011-09-30 0000876378 us-gaap:AdditionalPaidInCapitalMember 2012-01-01 2012-09-30 0000876378 us-gaap:AdditionalPaidInCapitalMember 2011-01-01 2011-12-31 0000876378 2011-01-01 2011-12-31 0000876378 us-gaap:AdditionalPaidInCapitalMember 2005-09-16 2005-12-31 0000876378 2005-09-16 2005-12-31 0000876378 sfes:TwoThousandTwelvePipeInvestorsMember 2012-02-01 2012-02-29 0000876378 2011-12-31 0000876378 2011-01-31 2011-12-30 0000876378 2012-07-01 2012-09-30 0000876378 2011-07-01 2011-09-30 0000876378 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2010-01-01 2010-01-31 0000876378 us-gaap:SeriesAPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2010-01-01 2010-01-31 0000876378 us-gaap:SeriesAPreferredStockMember 2010-01-01 2010-01-31 0000876378 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2009-07-01 2009-07-31 0000876378 us-gaap:SeriesAPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2009-07-01 2009-07-31 0000876378 us-gaap:SeriesAPreferredStockMember 2009-07-01 2009-07-31 0000876378 us-gaap:CommonStockMember 2008-12-01 2008-12-30 0000876378 us-gaap:AdditionalPaidInCapitalMember 2008-12-01 2008-12-30 0000876378 2008-12-01 2008-12-30 0000876378 sfes:CreightonRoyaltyAgreementMember 2012-01-01 2012-09-30 0000876378 sfes:SeriesPreferredConversionMember us-gaap:AdditionalPaidInCapitalMember 2010-01-01 2010-12-31 0000876378 sfes:SeriesPreferredConversionMember 2010-01-01 2010-12-31 0000876378 sfes:TwoThousandTwelvePipeInvestorsMember 2012-02-17 0000876378 2012-09-30 0000876378 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2010-01-01 2010-12-31 0000876378 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2009-01-01 2009-12-31 0000876378 us-gaap:CommonStockMember 2010-06-01 2010-06-30 0000876378 us-gaap:AdditionalPaidInCapitalMember 2010-06-01 2010-06-30 0000876378 2010-06-01 2010-06-30 0000876378 us-gaap:CommonStockMember 2008-05-01 2008-05-31 0000876378 us-gaap:AdditionalPaidInCapitalMember 2008-05-01 2008-05-31 0000876378 2008-05-01 2008-05-31 0000876378 us-gaap:AdditionalPaidInCapitalMember 2008-01-01 2008-12-31 0000876378 2008-01-01 2008-12-31 0000876378 us-gaap:CommonStockMember 2008-01-01 2008-12-31 0000876378 2005-09-16 2012-09-30 0000876378 us-gaap:SeriesAPreferredStockMember 2005-09-16 2012-09-30 0000876378 sfes:SeriesPreferredConversionMember 2005-09-16 2012-09-30 0000876378 us-gaap:PreferredStockMember sfes:SeriesPreferredConversionMember 2010-01-01 2010-12-31 0000876378 us-gaap:CommonStockMember 2010-01-01 2010-12-31 0000876378 us-gaap:PreferredStockMember 2010-09-01 2010-09-30 0000876378 us-gaap:CommonStockMember 2010-09-01 2010-09-30 0000876378 us-gaap:AdditionalPaidInCapitalMember 2010-09-01 2010-09-30 0000876378 us-gaap:MinimumMember 2008-01-08 0000876378 us-gaap:MaximumMember 2008-01-08 0000876378 2011-01-01 2011-09-30 0000876378 us-gaap:AdditionalPaidInCapitalMember 2010-01-01 2010-12-31 0000876378 2010-01-01 2010-12-31 0000876378 us-gaap:AdditionalPaidInCapitalMember 2009-01-01 2009-12-31 0000876378 2009-01-01 2009-12-31 0000876378 2012-11-10 0000876378 2012-01-01 2012-09-30 xbrli:pure sfes:Investor iso4217:USD xbrli:shares xbrli:shares iso4217:USD

NOTE 1 – BASIS OF PRESENTATION AND LIQUIDITY The following (a) condensed consolidated balance sheet as of December 31, 2011, which has been derived from audited financial statements, and (b) the unaudited condensed consolidated interim financial statements of SafeStitch Medical, Inc. (“SafeStitch” or the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the nine months ended September 30, 2012 are not necessarily indicative of results that may be expected for the year ending December 31, 2012. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2011 included in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (“SEC”) on March 30, 2012. SafeStitch Medical, Inc. (together with its consolidated subsidiaries, “SafeStitch” or the “Company”) is a developmental stage medical device company focused on the development of medical devices that manipulate tissues for endoscopic and minimally invasive surgery for the treatment of obesity, gastroesophageal reflux disease (“GERD”), Barrett’s Esophagus, esophageal obstructions, upper gastrointestinal bleeding, hernia formation and other intraperitoneal abnormalities. Cellular Technical Services Company, Inc. (“Cellular”), a non-operating public company, was incorporated in 1988 as NCS Ventures Corp. under the laws of the State of Delaware. On July 25, 2007 Cellular entered into a Share Transfer, Exchange and Contribution Agreement (the “Share Exchange”) with SafeStitch LLC, a Virginia limited liability company. On September 4, 2007, Cellular acquired all of the members’ equity interests in SafeStitch LLC in exchange for 11,256,369 shares of Cellular’s common stock, which represented a majority of Cellular’s outstanding shares immediately following the Share Exchange. Effective January 8, 2008, Cellular changed its name to SafeStitch Medical, Inc. and increased the aggregate number of shares of capital stock that may be issued from 35,000,000 to 250,000,000, comprising 225,000,000 shares of common stock, par value $0.001 per share (the “Common Stock”), and 25,000,000 shares of preferred stock, par value $0.01 per share. For accounting purposes, the acquisition has been treated as a recapitalization of SafeStitch LLC, with SafeStitch LLC as the acquirer (reverse acquisition). The historical financial statements prior to September 4, 2007 are those of SafeStitch LLC, which began operations on September 15, 2005. The accompanying financial statements give retroactive effect to the recapitalization as if it had occurred on September 15, 2005 (inception). The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. For the period from September 15, 2005 (inception) through September 30, 2012, the Company has accumulated a deficit of $28.3 million and has not generated positive cash flows from operations. The Company has been dependent upon equity financing and loans from stockholders to meet its obligations and sustain operations. The Company’s efforts have been principally devoted to developing its technologies and commercializing its products. Based upon its current cash position, availability under the extended term of its $4.0 million Note and Security Agreement (the “Credit Facility”) with both The Frost Group LLC (“The Frost Group”) and the Company’s President and CEO, Jeffrey G. Spragens, and by monitoring its discretionary expenditures, management believes that the Company may be able to fund its existing operations through June 30, 2013 when the Credit Facility matures. However, given the short time period until the Credit Facility matures and the probable inability to pay back the amounts due at maturity on June 30, 2013, the Company is exploring more permanent or longer term financing alternatives. The Company does not currently generate sufficient revenue from sales of the AMID™ Hernia Fixation Device (the “AMID HFD”) and external financing will therefore be necessary in order to fund the Company’s planned operations, including the continued development of our Intraluminal Gastroplasty Device for Obesity and GERD (“Gastroplasty Device”), and the anticipated expansion in 2013 of clinical trials for certain of the Company’s product candidates. The Company has taken several steps to preserve cash, including eliminating staff and focusing efforts solely on sales of the AMID HFD and development of our Gastroplasty Device. If adequate funds are not available, the Company may be required to delay, further reduce the scope of or eliminate its research and development programs, reduce its planned commercialization efforts or obtain funds through arrangements with collaborators or others that may require the Company to relinquish rights to certain product candidates that it might otherwise seek to develop or commercialize independently. Although the Company is seeking to secure additional funds through the issuance of equity and/or debt, no assurance can be given that additional financing will be available to the Company on acceptable terms, or at all. Unless the Credit Facility Maturity Date is extended or replaced with similar terms, additional funding will be required to repay both the Credit Facility and to continue operations. This uncertainty, along with the Company’s limited remaining cash balances, raises substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might be necessary as a result of the outcome of such uncertainty. In addition to securing additional funds, the Company’s ability to continue as a going concern is ultimately dependent upon generating revenues from those products that do not require further marketing clearance by the U.S. Food and Drug Administration (“FDA”), obtaining FDA clearance to market its other product candidates, and achieving profitable operations and generating sufficient cash flows from operations to meet future obligations.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Consolidation. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Isis Tele-Communications, Inc., which has no current operations, and SafeStitch LLC. All inter-company accounts and transactions have been eliminated in consolidation. Use of estimates. The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions, such as useful lives of property and equipment, that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Cash and cash equivalents. We consider all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company holds cash and cash equivalent balances in banks and other financial institutions, and includes overnight repurchase agreements collateralizing its depository bank accounts (sweep accounts) in its cash balances. Balances in excess of Federal Deposit Insurance Corporation (“FDIC”) limitations may not be insured. Allowances for Doubtful Accounts. The Company provides an allowance for receivables it believes it may not collect in full. Receivables are written off when they are deemed to be uncollectible and all collection attempts have ceased. The amount of bad debt recorded each period and the resulting adequacy of the allowance for doubtful accounts at the end of each period are determined using a combination of customer-by-customer analysis of the Company’s accounts receivable each period and subjective assessments of the Company’s future bad debt exposure. Inventories. Inventories are stated at lower of cost or market using the weighted average cost method and are evaluated for impairment when conditions exist that suggests impairment may be necessary. The $1.7 million inventory balance at September 30, 2012 consists of $1.0 million in components, $664,000 in finished units of the AMID HFD and $19,000 in standard mesh. Scrap materials and quality testing costs are included in Cost of Goods Sold (“COGS”), as incurred. Provisions for potentially obsolete or slow-moving inventory are made based on management’s analysis of inventory levels, obsolescence and future sales forecasts. Property and equipment. Property and equipment are carried at cost less accumulated depreciation. Major additions and improvements are capitalized, while maintenance and repairs that do not extend the lives of assets are expensed. Gain or loss, if any, on the disposition of fixed assets is recognized currently in operations. Depreciation is calculated primarily on a straight-line basis over estimated useful lives of the assets. Revenue Recognition. Revenue from product sales is recognized when persuasive evidence of an arrangement exists, the goods are shipped and title has transferred, the price is fixed or determinable, and the collection of the sales proceeds is reasonably assured. Advertising Costs. The Company expenses all costs of advertising as incurred. Advertising and promotional costs are included in selling, general and administrative costs and expenses for all periods presented, and totaled $22,000 and $106,000, respectively, for the three and nine months ended September 30, 2012. Advertising and promotional costs and expenses totaled $2,000 and $11,000, respectively, for the three and nine months ended September 30, 2011. Research and development. Research and development costs principally represent salaries of the Company’s medical and biomechanical engineering professionals, material and shop costs associated with manufacturing product prototypes and payments to third parties for clinical trials and additional product development and testing. All research and development costs are charged to expense as incurred. Patent costs. Costs incurred in connection with acquiring patent rights and the protection of proprietary technologies are charged to expense as incurred. Stock-based compensation. The Company accounts for all share-based payments to employees and directors, based on their grant date fair values. Compensation for share-based payments to non-employees is based on the fair value at the measurement date, which is generally the performance completion date. The fair value is initially measured at the grant date and subsequently measured at each reporting period until the final measurement date. The fair value of the Company’s stock option awards is expensed over the vesting life of the underlying stock options using the graded vesting method, with each tranche of vesting options valued separately. Stock-based compensation is included in general and administrative costs and expenses for all periods presented. Therapeutic discovery project tax credit. The Company records the therapeutic discovery project tax credit on an accrual basis when the credit is considered realized, which is generally when approved by the government agency. Such credit is reported as other income in the accompanying financial statements. Fair value of financial instruments. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and notes payable approximate fair value based on their short-term maturity. Related party receivables and stockholder loans are carried at cost. Long-lived assets. The Company reviews the carrying values of its long-lived assets for possible impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be recoverable. Any long-lived assets held for disposal are reported at the lower of their carrying amounts or fair value less costs to sell. Income taxes. The Company follows the liability method of accounting for income taxes, which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of the assets and liabilities. The Company’s policy is to record a valuation allowance against deferred tax assets, when the deferred tax asset is not recoverable. The Company considers estimated future taxable income or loss and other available evidence when assessing the need for its deferred tax valuation allowance. Comprehensive income (loss). Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. The Company’s comprehensive net loss is equal to its net loss for all periods presented, and, as a result, no statement of comprehensive income (loss) has been included in the condensed consolidated financial statements.

NOTE 3 – PROPERTY AND EQUIPMENT Property and equipment consist of the following:   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="51%"> </td> <td valign="bottom" width="10%"> </td> <td> </td> <td valign="bottom" width="10%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="10%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="center" style="border-bottom:1px solid #000000">Estimated Useful Lives</td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">September 30, 2012</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">December 31, 2011</td> <td valign="bottom"> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Machinery and equipment </td> <td valign="bottom"> </td> <td valign="bottom" align="center">5 years</td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">660,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">660,000</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Furniture, fixtures and leasehold improvements </td> <td valign="bottom"> </td> <td valign="bottom" align="center">3-5 years</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">87,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">81,000</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Software </td> <td valign="bottom"> </td> <td valign="bottom" align="center">3-5 years</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">57,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">57,000</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">804,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">798,000</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Accumulated depreciation and amortization </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(455,000</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(328,000</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> Property and equipment, net </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">349,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">470,000</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr>  </table> Depreciation of fixed assets utilized in research and development activities is included in research and development costs and expenses. All other depreciation is included in selling, general and administrative costs and expenses. Depreciation and amortization expense was $43,000 and $127,000, respectively for the three and nine months ended September 30, 2012, and was $43,000 and $100,000, respectively for the three and nine months ended September 30, 2011.

NOTE 4 – STOCK-BASED COMPENSATION On November 13, 2007, the Board of Directors and a majority of the Company’s stockholders approved the SafeStitch Medical, Inc. 2007 Incentive Compensation Plan (the “2007 Plan”), which was amended on June 19, 2012 to increase the number of shares of Common Stock available for issuance to 5,000,000. Under the 2007 Plan, which is administered by the Compensation Committee, the Company may grant stock options, stock appreciation rights, restricted stock and/or deferred stock to employees, officers, directors, consultants and vendors up to an aggregate of 5,000,000 shares of Common Stock, which are fully reserved for future issuance. The exercise price of stock options or stock appreciation rights may not be less than the fair market value of the Company’s shares at the date of grant and, within any 12 month period, no person may receive stock options or stock appreciation rights for more than one million shares. Additionally, no stock options or stock appreciation rights granted under the 2007 Plan may have a term exceeding ten years. The Company granted 813,500 and 562,500 stock options under the 2007 Plan during the nine months ended September 30, 2012 and 2011, respectively, including 218,000 and 68,000 stock options that were issued to consultants. The options granted during 2012 were issued at an exercise price ranging from $0.65 to $0.85 per share and had an estimated aggregate grant date fair value of $441,000. The options granted during 2011 were issued at an exercise price of $1.12 per share and had an estimated aggregate grant date fair value of $502,000. The weighted average grant date fair value of the options granted during the nine months ended September 30, 2012 and 2011 was $0.54 per share and $0.89 per share, respectively. Total stock-based compensation recorded for the three and nine months ended September 30, 2012 was $113,000 and $336,000, respectively. Total stock-based compensation recorded for the three and nine months ended September 30, 2011 was $98,000 and $240,000, respectively. The stock-based compensation recorded for the nine months ended September 30, 2011 included a credit of $113,000 for a change in forfeiture experience. All stock-based compensation is included in selling, general and administrative costs and expenses. The fair values of options granted are estimated on the date of their grant using the Black-Scholes option pricing model based on the assumptions included in the table below. The fair value of the Company’s stock option awards is expensed over the vesting life of the underlying stock options using the graded vesting method, with each tranche of vesting options valued separately. Expected volatility is based on the historical volatility of the Common Stock. The risk-free interest rate for periods within the contractual life of the stock option award is based on the yield of U.S. Treasury bonds on the grant date with a maturity equal to the expected term of the stock option. The expected life of stock option awards granted to employees and non-employee directors is based upon the “simplified” method for “plain vanilla” options described in SEC Staff Accounting Bulletin No. 107, as amended by SEC Staff Accounting Bulletin No. 110. The expected life of all other stock option awards is the contractual term of the option. Forfeiture rates are based on management’s estimates. The fair value of each option granted during the nine months ended September 30, 2012 and 2011 was estimated using the following assumptions. <table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="60%"> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td valign="bottom" width="3%"> </td> <td> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="center" style="border-bottom:1px solid #000000">Nine months ended September 30, 2012</td> <td valign="bottom"> </td> <td valign="bottom" align="center" style="border-bottom:1px solid #000000">Nine months ended September 30, 2011</td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Expected volatility </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap" align="center">85.41% - 111.36%</td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap" align="center">76.91% - 102.63%</td> </tr> <tr> <td valign="top"> Expected dividend yield </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap" align="center">0.00%</td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap" align="center">0.00%</td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Risk-free interest rate </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap" align="center">1.02% – 1.98%</td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap" align="center">2.25% – 3.25%</td> </tr> <tr> <td valign="top"> Expected life </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap" align="center">5.5 – 10.0 years</td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap" align="center">5.5 – 10.0 years</td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Forfeiture rate </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap" align="center">0% - 2%</td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap" align="center">0% - 5%</td> </tr>  </table> The following summarizes the Company’s stock option activity for the nine months ended September 30, 2012:   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="62%"> </td> <td valign="bottom" width="6%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="6%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="6%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="6%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Shares</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Weighted Average Exercise Price</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Weighted Average Remaining Contractual Term (Years)</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Aggregate Intrinsic Value</td> <td valign="bottom"> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Outstanding at December 31, 2011 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,628,167</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.35</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.26</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr> <td valign="top"> Granted </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">813,500</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.66</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9.39</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Exercised </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr> <td valign="top"> Canceled or expired </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(237,667</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.99</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Outstanding at September 30, 2012 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,204,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.02</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.09</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> Exercisable at September 30, 2012 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">990,875</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.24</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.41</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Vested and expected to vest at September 30, 2012 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,155,239</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.03</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.05</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr>  </table> None of the 813,500 options granted during the first nine months of the Company’s 2012 fiscal year were vested as of September 30, 2012. At September 30, 2012, there was approximately $333,000 of total unrecognized compensation cost related to non-vested employee and director share-based compensation arrangements. That cost is expected to be recognized over a weighted-average period of 1.53 years. No options were exercised during the three and nine months ended September 30, 2012 and 2011. No tax benefits were attributed to the stock-based compensation expense because a valuation allowance was maintained for substantially all net deferred tax assets.

NOTE 5 – DEBT Credit Facility. In connection with the acquisition of SafeStitch LLC, the Company entered into a Note and Security Agreement (the “Credit Facility”) with both The Frost Group and Jeffrey G. Spragens, the Company’s Chief Executive Officer and President and a director. The Frost Group is a Florida limited liability company whose members include Frost Gamma Investments Trust (“Frost Gamma”), a trust controlled by Dr. Phillip Frost, the largest beneficial holder of the issued and outstanding shares of Common Stock, Dr. Jane H. Hsiao, the Company’s Chairman of the Board, and Steven D. Rubin, a director. The Credit Facility provides $4.0 million in total available borrowings, consisting of $3.9 million from The Frost Group and $100,000 from Mr. Spragens. The Company has granted a security interest in all present and subsequently acquired collateral in order to secure prompt, full and complete payment of the amounts outstanding under the Credit Facility. The collateral includes all assets of the Company, inclusive of intellectual property (patents, patent rights, trademarks, service marks, etc.). Outstanding borrowings under the Credit Facility accrue interest at a 10% annual rate. The Credit Facility had an initial term of 28 months, expiring in December 2009, and was amended on four occasions to extend the Maturity Date, which is now June 30, 2013. In connection with the Credit Facility, the Company granted warrants to purchase an aggregate of 805,521 shares of Common Stock to The Frost Group and Mr. Spragens. The fair value of the warrants was determined to be $1,985,000 on the grant date based on the Black-Scholes valuation model using the following assumptions: expected volatility of 82%, dividend yield of 0%, risk-free interest rate of 4.88% and expected life of 10 years. The fair value of the warrants was recorded as deferred financing costs and is being amortized over the life of the Credit Facility. The Company recorded amortization expense related to these deferred financing costs of $2,000 and $7,000, respectively, for the three and nine months ended September 30, 2012 and $5,000 and $36,000, respectively, for the three and nine months ended September 30, 2011. In October 2012, The Frost Group and Mr. Spragens exercised the warrants for the purchase of 805,521 shares of Common Stock. The Company borrowed $300,000 under the Credit Facility during September 2012. The Company did not recognized interest expense related to the outstanding borrowings under the Credit Facility for the three months ended September 30, 2012. The Company has a $300,000 outstanding balance and $3,700,000 available under the Credit Facility as of September 30, 2012.

NOTE 6 – CAPITAL TRANSACTIONS 2012 Private Placement of Common Stock. On February 17, 2012, the Company entered into a stock purchase agreement (the “2012 Stock Purchase Agreement”) with 35 investors (the “2012 PIPE Investors”) pursuant to which the 2012 PIPE Investors agreed to purchase an aggregate of 20,794,000 shares of Common Stock (the “2012 PIPE Shares”) at a price of $0.40 per share for aggregate consideration of $8.3 million. Among the Investors purchasing Shares were Frost Gamma, Dr. Jane Hsiao, the Company’s Chairman of the Board, Jeffrey Spragens, the Company’s President and Chief Executive Officer and Richard Pfenniger, a member of the Company’s Board of Directors. Frost Gamma and Dr. Hsiao each purchased 4,500,000 shares, Mr. Spragens purchased 250,000 shares, and Mr. Pfenniger purchased 125,000 shares. The Company issued the 2012 PIPE Shares in reliance upon the exemption from registration under Section 4(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506 of Regulation D promulgated thereunder.

NOTE 7 – BASIC AND DILUTED NET LOSS PER SHARE Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period reported. Diluted net loss per common share is computed giving effect to all dilutive potential common shares that were outstanding for the period reported. Diluted potential common shares consist of incremental shares issuable upon exercise of stock options and warrants and conversion of preferred stock. In computing diluted net loss per share for the three and nine months ended September 30, 2012 and 2011, no adjustment has been made to the weighted average outstanding common shares as the assumed exercise of outstanding options and warrants and conversion of preferred stock is anti-dilutive. Potential common shares not included in calculating diluted net loss per share are as follows:   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="64%"> </td> <td valign="bottom" width="9%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="9%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">September 30, 2012</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">September 30, 2011</td> <td valign="bottom"> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Stock options </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,204,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,629,667</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Stock warrants </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">805,521</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">805,521</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Total </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,009,521</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,435,188</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr>  </table>

NOTE 8 – COMMITMENTS AND CONTINGENCIES The Company is obligated under various operating lease agreements for office space. Generally, the lease agreements require the payment of base rent plus escalations for increases in building operating costs and real estate taxes. Rental expense under operating leases amounted to $76,000 and $209,000 for the three and nine months ended September 30, 2012, respectively, and $58,000 and $163,000 for the three and nine months ended September 30, 2011, respectively. The Company is obligated to pay royalties to Creighton University (“Creighton”) on the sales of products licensed from Creighton pursuant to an exclusive license and development agreement (see Note 9). The Company is also obligated under an agreement with Dr. Parviz Amid to pay a 4% royalty to Dr. Amid on the sales of any product developed with Dr. Amid’s assistance, including the AMID HFD, for a period of ten years from the first commercial sale of such product. Royalties to Dr. Parviz Amid in the amount of $400 and $800 have been incurred during the three and nine months ended September 30, 2012, respectively. No royalties have been incurred or paid for the three and nine months ended September 30, 2011. The Company has placed orders with various suppliers for the purchase of certain tooling, contract engineering and research services. Each of these orders has a duration or expected completion within the next twelve months. The Company currently has no material commitments with terms beyond twelve months.

NOTE 9 – AGREEMENT WITH CREIGHTON UNIVERSITY On May 26, 2006, SafeStitch LLC entered into an exclusive license and development agreement (the “Creighton Agreement”) with Creighton, granting the Company a worldwide exclusive (even as to the university) license, with rights to sublicense, to all the Company’s product candidates and associated know-how based on Creighton technology, including the exclusive right to manufacture, use and sell the product candidates. Pursuant to the Creighton Agreement, the Company is obligated to pay Creighton, on a quarterly basis, a royalty of 1.5% of the revenue collected worldwide from the sale of any product licensed under the Creighton Agreement, less certain amounts including, without limitation, chargebacks, credits, taxes, duties and discounts or rebates. The Creighton Agreement does not provide for minimum royalties. Also pursuant to the Creighton Agreement, the Company agreed to invest, in the aggregate, at least $2.5 million over 36 months, beginning May 26, 2006, towards development of any licensed product. This $2.5 million investment obligation excluded the first $150,000 of costs related to the prosecution of patents, which the Company invested outside of the Creighton Agreement. The Company is further obligated to pay to Creighton an amount equal to 20% of certain of the Company’s research and development expenditures as reimbursement for the use of Creighton’s facilities. Failure to comply with the payment obligations above will result in all rights in the licensed patents and know-how reverting back to Creighton. As of December 31, 2007, the Company had satisfied the $2.5 million investment obligation described above. The Company recorded research and development costs and expenses related to the 20% facility reimbursement obligation totaling approximately $10,000 and $34,000, respectively for the three and nine months ended September 30, 2012, and $12,000 and $33,000, respectively, for the three and nine months ended September 30, 2011.

NOTE 10 – INCOME TAXES The Company accounts for income taxes using the asset and liability method, the objective of which is to establish deferred tax assets and liabilities for the temporary differences between the financial reporting and the tax bases of the Company’s assets and liabilities at enacted tax rates expected to be in effect when such amounts are realized or settled. A valuation allowance related to deferred tax assets is recorded when it is more likely than not that some portion or all of the deferred tax assets will not be realized. All of the Company’s deferred tax assets have been fully reserved by a valuation allowance due to management’s uncertainty regarding the future profitability of the Company. The Company has recognized no adjustment for uncertain tax provisions. SafeStitch recognizes interest and penalties related to uncertain tax positions in selling, general and administrative costs and expenses; however no such provisions for accrued interest and penalties related to uncertain tax positions have been recorded as of September 30, 2012 or December 31, 2011. The tax years 2009-2011 remain open to examination by the major tax jurisdictions in which the Company operates.

NOTE 11 – CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS As more fully described in Note 5, the Company entered into a $4.0 million Credit Facility with both Jeffrey G. Spragens, the Company’s President, Chief Executive Officer and director, and The Frost Group. The Company entered into a five-year lease for office space in Miami, Florida with a company controlled by Dr. Frost. The non-cancelable lease, which commenced January 1, 2008, provides for a 4.5% annual rent increase over the life of the lease. The Miami office lease was amended in August 2011 to include additional office space in the same building, and current rental payments under the lease are approximately $19,000 per month. The Company recorded rent expense related to the Miami lease totaling approximately $73,000 and $198,000, respectively, for the three and nine months ended September 30, 2012, and $51,000 and $145,000, respectively, for the three and nine months ended September 30, 2011. Dr. Hsiao, Dr. Frost and director Steven Rubin are each significant stockholders and/or directors of Non-Invasive Monitoring Systems, Inc. (“NIMS”), a publicly-traded medical device company, Aero Pharmaceuticals, Inc. (“Aero”), a privately-held pharmaceutical distribution company that dissolved in December 2011, Tiger X Medical, Inc. (“Tiger X”) (formerly known as Cardo Medical, Inc.), a publicly-traded former medical device company, and SearchMedia Holdings Limited (“SearchMedia”), a publicly-traded media company operating primarily in China, and Sorrento Therapeutics, Inc. (“Sorrento”), a publicly-traded development stage biopharmaceutical company. Director Richard Pfenniger is also a shareholder of NIMS. The Company’s Chief Financial Officer also serves as the Chief Financial Officer and supervises the accounting staffs of NIMS and, until its dissolution, Aero, under a Board-approved cost sharing arrangement whereby the total salaries of the accounting staffs of the three companies are shared. Aero has not participated in the cost sharing arrangement since June 30, 2011 and was dissolved in December 2011. Since December 2009, the Company’s Chief Legal Officer has served under a similar Board-approved cost sharing arrangement as Corporate Counsel of SearchMedia and as the Chief Legal Officer of each of NIMS and Tiger X, and from June 2011 through September 19, 2012, as Corporate Counsel for Sorrento. The Company has recorded reductions to selling, general and administrative costs and expenses to account for the sharing of costs under these arrangements of $51,000 and $154,000, respectively, for the three and nine months ended September 30, 2012, and $51,000 and $205,000, respectively, for the three and nine months ended September 30, 2011. Aggregate accounts receivable from NIMS, Aero, Tiger X, Sorrento and SearchMedia were approximately $45,000 and $66,000 as of September 30, 2012 and December 31, 2011, respectively.

NOTE 12 – EMPLOYEE BENEFIT PLANS Effective May 1, 2008, the SafeStitch 401(k) Plan (the “401k Plan”) permits employees to contribute up to 100% of qualified annual compensation up to annual statutory limitations. Employee contributions may be made on a pre-tax basis to a regular 401(k) account or on an after-tax basis to a “Roth” 401(k) account. The Company contributes to the 401k Plan a “safe harbor” match of 100% of each participant’s contributions to the 401k Plan up to a maximum of 4% of the participant’s qualified annual earnings. The Company recorded 401(k) Plan matching expense of approximately $23,000 and $37,000, respectively, for the three and nine months ended September 30, 2012 and $9,000 and $28,000, respectively, for the three and nine months ended September 30, 2011.

Use of estimates. The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions, such as useful lives of property and equipment, that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

Cash and cash equivalents. We consider all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company holds cash and cash equivalent balances in banks and other financial institutions, and includes overnight repurchase agreements collateralizing its depository bank accounts (sweep accounts) in its cash balances. Balances in excess of Federal Deposit Insurance Corporation (“FDIC”) limitations may not be insured.

Allowances for Doubtful Accounts. The Company provides an allowance for receivables it believes it may not collect in full. Receivables are written off when they are deemed to be uncollectible and all collection attempts have ceased. The amount of bad debt recorded each period and the resulting adequacy of the allowance for doubtful accounts at the end of each period are determined using a combination of customer-by-customer analysis of the Company’s accounts receivable each period and subjective assessments of the Company’s future bad debt exposure.

Inventories. Inventories are stated at lower of cost or market using the weighted average cost method and are evaluated for impairment when conditions exist that suggests impairment may be necessary. The $1.7 million inventory balance at September 30, 2012 consists of $1.0 million in components, $664,000 in finished units of the AMID HFD and $19,000 in standard mesh. Scrap materials and quality testing costs are included in Cost of Goods Sold (“COGS”), as incurred. Provisions for potentially obsolete or slow-moving inventory are made based on management’s analysis of inventory levels, obsolescence and future sales forecasts.

Property and equipment. Property and equipment are carried at cost less accumulated depreciation. Major additions and improvements are capitalized, while maintenance and repairs that do not extend the lives of assets are expensed. Gain or loss, if any, on the disposition of fixed assets is recognized currently in operations. Depreciation is calculated primarily on a straight-line basis over estimated useful lives of the assets.

Advertising Costs. The Company expenses all costs of advertising as incurred. Advertising and promotional costs are included in selling, general and administrative costs and expenses for all periods presented, and totaled $22,000 and $106,000, respectively, for the three and nine months ended September 30, 2012. Advertising and promotional costs and expenses totaled $2,000 and $11,000, respectively, for the three and nine months ended September 30, 2011.

Stock-based compensation. The Company accounts for all share-based payments to employees and directors, based on their grant date fair values. Compensation for share-based payments to non-employees is based on the fair value at the measurement date, which is generally the performance completion date. The fair value is initially measured at the grant date and subsequently measured at each reporting period until the final measurement date. The fair value of the Company’s stock option awards is expensed over the vesting life of the underlying stock options using the graded vesting method, with each tranche of vesting options valued separately. Stock-based compensation is included in general and administrative costs and expenses for all periods presented.

Income taxes. The Company follows the liability method of accounting for income taxes, which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of the assets and liabilities. The Company’s policy is to record a valuation allowance against deferred tax assets, when the deferred tax asset is not recoverable. The Company considers estimated future taxable income or loss and other available evidence when assessing the need for its deferred tax valuation allowance.

Comprehensive income (loss). Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. The Company’s comprehensive net loss is equal to its net loss for all periods presented, and, as a result, no statement of comprehensive income (loss) has been included in the condensed consolidated financial statements.

Property and equipment consist of the following:   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="51%"> </td> <td valign="bottom" width="10%"> </td> <td> </td> <td valign="bottom" width="10%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="10%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="center" style="border-bottom:1px solid #000000">Estimated Useful Lives</td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">September 30, 2012</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">December 31, 2011</td> <td valign="bottom"> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Machinery and equipment </td> <td valign="bottom"> </td> <td valign="bottom" align="center">5 years</td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">660,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">660,000</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Furniture, fixtures and leasehold improvements </td> <td valign="bottom"> </td> <td valign="bottom" align="center">3-5 years</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">87,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">81,000</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Software </td> <td valign="bottom"> </td> <td valign="bottom" align="center">3-5 years</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">57,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">57,000</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">804,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">798,000</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Accumulated depreciation and amortization </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(455,000</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(328,000</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> Property and equipment, net </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">349,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">470,000</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr>  </table>

The following summarizes the Company’s stock option activity for the nine months ended September 30, 2012:   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="62%"> </td> <td valign="bottom" width="6%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="6%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="6%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="6%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Shares</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Weighted Average Exercise Price</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Weighted Average Remaining Contractual Term (Years)</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Aggregate Intrinsic Value</td> <td valign="bottom"> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Outstanding at December 31, 2011 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,628,167</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.35</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.26</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr> <td valign="top"> Granted </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">813,500</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.66</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9.39</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Exercised </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr> <td valign="top"> Canceled or expired </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(237,667</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.99</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Outstanding at September 30, 2012 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,204,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.02</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.09</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> Exercisable at September 30, 2012 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">990,875</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.24</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.41</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Vested and expected to vest at September 30, 2012 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,155,239</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.03</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.05</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr>  </table>

false --12-31 Q3 2012 2012-09-30 10-Q 0000876378 48797755 Smaller Reporting Company SafeStitch Medical, Inc. 200000 200000 500000 500000 200000 200000 500000 500000 113000 250000000 35000000 4366000 4366000 4366000 36000 4000 -40000 4366000 -4000000 P28M 4301000 700000 1985000 4301000 4301000 139000 8000 10000 10000 2.15 2.15 2.15 1.00 1.00 1.00 2000000 2000000 1982000 1962000 20000 1998000 1978000 20000 P5Y 1000000 P10Y 2500000 3192000 35 5063000 5063000 150000 4000 0.045 0.04 0.015 0.04 P12M P36M P10Y P12M 1.22 1.22 1.22 1.00 1.00 1.00 1.00 1.00 1.00 6135000 1100000 800000 0 205000 51000 154000 51000 0.20 5751000 2975000 33000 12000 34000 10000 P10Y P10Y 0.05 0.02 P5Y6M P5Y6M 0.00 0.00 P5Y4M28D 502000 441000 P9Y4M21D P6Y3M4D P7Y1M2D P7Y18D 77000 84000 0.40 805521 1985000

469000

860000

9000

328000

455000

20762000

29396000

4301000

1000

239000

195000

471000

335000

337000

11000

2000

240000

98000

336000

113000

36000

5000

7000

2000

2435188

1629667

805521

3009521

2204000

805521

993000

2300000

507000

1942000

11256369

3032000

328000

298000

118000

-2704000

180000

5000000

0.001

0.40

225000000

697000

28003755

48797755

20794000

28003755

48797755

28000

49000

4000000

179000

8000

27240000

4107000

1481000

5307000

1379000

2013-06-30

14000

7000

28000

9000

37000

23000

1.00

469000

100000

127000

100000

43000

127000

43000

22789000

28305000

366000

5001000

66000

45000

2523000

300000

-0.15

-0.05

-0.12

-0.03

P1Y6M11D

333000

0.00

P10Y

0.82

0.0488

-20000

903000

-159000

3000

-28305000

-4150000

-1493000

-5516000

-1378000

576000

194000

391000

7000

-48000

1826000

-5000

1687000

117000

8000

-72000

2000

155000

7000

43000

155000

91000

664000

1687000

1000000

19000

79000

993000

2300000

469000

860000

300000

2013-06-30

300000

0.10

4000000

3900000

4000000

100000

3700000

26302000

1051000

6143000

69000

-199000

-6000

-26253000

-3556000

-6317000

-76000

-28305000

-1060000

-3041000

-5185000

-2366000

-5303000

-4150000

-5758000

-1493000

-5516000

-1378000

-33672000

-4150000

-1493000

-5516000

-1378000

-906000

-43000

-12000

-50000

-2000

-27399000

-4107000

-1481000

-5466000

-1376000

163000

145000

58000

51000

19000

209000

198000

76000

73000

16000

9000

1147000

838000

199000

6000

366000

0.01

25000000

143000

83000

1431000

17280000

8318000

3980000

141000

903000

35000

798000

81000

660000

57000

804000

87000

660000

57000

470000

349000

P5Y

P3Y

P5Y

P3Y

141000

49000

15441000

2480000

975000

2504000

557000

28300000

800

400

20000

11000

2000

11799000

1627000

506000

2803000

822000

1642000

240000

337000

0.0000

1.0263

1.1136

0.7691

0.8541

0.0325

0.0198

0.0225

0.0102

990875

1.24

237667

1.99

562500

68000

813500

218000

0.89

0.54

1628167

2204000

1.35

1.02

2155239

1.03

1.12

0.66

0.85

0.65

11256000

16093000

17963000

2000000

28004000

48798000

-75000

-76000

1000

369000

-1136000

1494000

11000

2421000

-4177000

6582000

16000

1473000

-9362000

10817000

18000

1284000

-11728000

12974000

18000

20000

3424000

-17031000

20427000

28000

-1999000

-22789000

20762000

28000

1140000

-28305000

29396000

49000

697000

20794000

1862000

4978000

20794000

4500000

125000

250000

4500000

11256000

4837000

-1000

1000

8318000

8297000

21000

3988000

3986000

2000

4974000

4969000

5000

8300000

1504000

1493000

11000

5093000

5088000

5000

28004000

45155000

48798000

1977000

36000

5000

7000

2000